Research programme: cancer therapeutics - Emiliem

Drug Profile

Research programme: cancer therapeutics - Emiliem

Alternative Names: EM 100; EM 101; EM 300; EM 370; EM 400; Molecular targeted therapeutics - Emiliem

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emiliem; National Institutes of Health (USA)
  • Developer Emiliem
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Angiogenesis inhibitors; MTOR protein inhibitors; Phosphotransferase inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 22 Nov 2008 Applied Biosystems Inc has merged with Invitrogen Corporation to form Life Technologies Corporation
  • 24 Apr 2008 Emiliem receives a worldwide license for a series of compounds from the NIH
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top